|Other Names||Down syndrome critical region protein 3, Down syndrome critical region protein A, DSCR3, DCRA, DSCRA|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6319a was selected from the N-term region of human DSCR3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Tissue Location||Ubiquitously expressed.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The region of chromosome 21 between genes CBR and ERG (CBR-ERG region), which spans 2.5 Mb on 21q22.2, has been defined by analysis of patients with partial trisomy 21. It contributes significantly to the pathogenesis of many characteristics of Down syndrome, including morphological features, hypotonia, and mental retardation. The DSCR3 (Down syndrome critical region gene 3) gene is found in this region and is predictated to contain eight exons. DSCR3 is expressed in most tissues examined.
Dahmane, N., et al., Genomics 48(1):12-23 (1998).Nakamura, A., et al., J. Biochem. 122(4):872-877 (1997).
If you have any additional inquiries please email technical services at email@example.com.